iTeos Therapeutics is a privately-held, clinical-stage biopharmaceutical company dedicated to extending and improving the lives of cancer patients by designing and developing next generation immunotherapies.
Based in Gosselies, Belgium and Cambridge, MA, iTeos Therapeutics was founded out of the Ludwig Institute for Cancer Research (LICR) and the de Duve Institute (UCLouvain) in 2011.
In March 2020, the Company completed a $125 million Series B2 financing, and in July 2020, we completed our IPO raising over $230million of gross proceeds. In June 2021, iTeos entered into a transformative $2.145 billion co-development and co-commercialization agreement with GSK for EOS-448, iTeos’s anti-TIGIT monoclonal antibody. As a well-capitalized biotech company, iTeos is positioned to continue to develop our pipeline and maintain investment in our discovery research team to leverage our expertise in tumor immunology to improve the lives of cancer patients.
For more information, please visit www.iteostherapeutics.com.
iTeos Therapeutics is now a world-class biotech in cancer immunotherapy. To carry on its growth, expand its pipeline and reinforce its team, iTeos Therapeutics is looking for a Head of Target Discovery and Validation.
The Head of Target Discovery and Validation is a senior role in the Research and Development Department and the successful applicant will have the chance to shape iTeos Therapeutic’s future pipeline programs. In collaboration with the Search and Evaluation cross functional team, he/she will play a key role in reviewing and selection of new targets and target biology for inclusion in the iTeos discovery pipeline. The role will involve managing a team of dedicated scientists but also work across the various functions at iTeos to interrogate the biology of novel targets, their regulation in disease, understand their expression patterns, their druggability, propose drug modalities and evaluate the relevant competitive space. He/she is responsible for driving internal target discovery efforts and the design, implementation, and management of research projects aimed at understanding mechanism of action and the validation of targets in immune-oncology. The ultimate aim is to recommend promising targets for further drug discovery efforts. The position also involves collaborating with external academics and contract research organization collaborators to accelerate new oncology therapies.
The successful candidate will have a strong R&D scientific and clinical background, proven project and people leadership, strategic acumen and excellent communication skills. In addition, the
candidate will have an ability to engage and collaborate across organizational boundaries with an entrepreneurial attitude by acting with urgency and agility.
Please send your CV together with an adapted cover letter to the following address : firstname.lastname@example.org. Please, mention the reference HTD-V in the mail object. Your application and related information will remain strictly confidential.
For our recruitments in Belgium, we closely collaborate with a Recruitment & Selection company, PaHRtners. Your application will be automatically forwarded to them. We, together with PaHRtners, will keep all your data confidential (GDPR compliant approach).